Originally published on Technavio: Biologics Contract Development and Manufacturing Organization (CDMO) Market Analysis North America,Europe,Asia,Rest of World (ROW) – US,Germany,France,China,Japan – Size and Forecast 2024-2028
The Biologics Contract Development and Manufacturing Organization (CDMO) Market is poised for substantial growth across key regions, including North America, Europe, Asia, and the Rest of the World (ROW), from 2024 to 2028. In North America, particularly in the United States, the market is expected to witness significant expansion. This growth is driven by factors such as increasing research and development activities in the biopharmaceutical sector, rising demand for outsourcing services to streamline production processes, and the presence of a robust regulatory framework supporting biologics development and manufacturing.
Similarly, in Europe, countries like Germany and France are anticipated to contribute significantly to the Biologics CDMO Market. The region’s established biopharmaceutical industry, supportive regulatory environment, and growing investments in biologics manufacturing infrastructure are driving market growth. Moreover, the increasing focus on personalized medicine and biologics-based therapies is fueling the demand for CDMO services in Europe.
In Asia, led by China and Japan, the Biologics CDMO Market is expected to witness rapid growth during the forecast period. The region’s expanding biopharmaceutical sector, favorable government policies promoting biologics manufacturing, and growing expertise in cell and gene therapy are driving market expansion. Additionally, the availability of skilled workforce and cost-effective manufacturing capabilities make Asia an attractive destination for biologics outsourcing.
In the Rest of the World (ROW) regions, which include emerging markets with diverse healthcare landscapes, the Biologics CDMO Market is also anticipated to witness growth opportunities. Countries in regions such as Latin America, the Middle East, and Africa are experiencing increasing investments in biopharmaceutical research and manufacturing capabilities. The growing demand for biologics-based therapies and the expansion of the pharmaceutical industry in these regions are driving the adoption of CDMO services.
To Learn deeper into this report , View Sample PDF
Overall, the period from 2024 to 2028 is expected to witness robust growth in the Biologics CDMO Market across key regions worldwide, driven by factors such as increasing outsourcing trends in the biopharmaceutical industry, advancements in biologics manufacturing technologies, and the growing demand for personalized medicine. Market players are expected to focus on expanding their service offerings, enhancing manufacturing capabilities, and strengthening their presence in emerging markets to capitalize on the evolving opportunities in the Biologics CDMO sector.
For more information please contact.
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: [email protected]
Website: www.technavio.com/